Dow Jones
38.111,48 -330,02 (-0,86%) Nasdaq
16.737,08 -183,52 (-1,08%) Nikkei 225
38.465,39 +411,29 (+1,08%) EUR/USD
1,0823 -0,0013 (-0,12%) Bitcoin EUR
63.130,16 +241,54 (+0,38%) CMC Crypto 200
1.429,89 -25,98 (-1,78%)
Mind Medicine (MindMed) Inc. (MNMD)
Dopo ore:
| Chiusura precedente | 8,91 |
| Aperto | 8,95 |
| Denaro | 8,76 x 500 |
| Domanda | 8,82 x 200 |
| Min-Max giorno | 8,73 - 9,14 |
| Intervallo di 52 settimane | 2,41 - 12,22 |
| Volume | |
| Media Volume | 2.394.892 |
| Capitalizzazione | 633,196M |
| Beta (mensile su 5 anni) | 2,48 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,93 |
| Prossima data utili | 01 ago 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 24,25 |
- GlobeNewswire
FCM Received Significant Support from Shareholders, Disappointed that “Passive” Investors Saw Fit to Give Incumbent Directors Another Chance to Disappoint
FCM Won the Majority of Retail Shareholders’ Vote and Thanks Them for Their Strong Support FCM Exhorts Institutions to Live Up to Touted Social Investment Goals and Closely Monitor MindMed Board and Management FCM Concerned MindMed Board and Management Will Continue Decimation of Shareholder Value FCM Intends to Continue its Fight for Shareholder Value, and to Hold the Board and Management Accountable for MindMed’s Performance SHERIDAN, Wyo., June 22, 2023 (GLOBE NEWSWIRE) -- Today, FCM MM HOLDI
- GlobeNewswire
FCM Denounces MindMed’s Manipulation of Corporate Machinery to Protect Incumbent Board of Directors
FCM Believes MindMed Is Threatening to Violate NASDAQ Requirements Imperiling MindMed’s Listing and Future Liquidity for Shareholders Failure to Satisfy Quorum Requirement at Annual Meeting Demonstrates Lack of Shareholder Support FCM Believes MindMed’s Announced Plan to Hold Shareholder Meeting Regardless of Level of Shareholder Participation Represents Appalling Corporate Governance Vote on FCM’s BLUE Proxy to Restore Shareholder Value SHERIDAN, Wyo., June 15, 2023 (GLOBE NEWSWIRE) -- Today, F
- GlobeNewswire
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
FCM Confident in Ability to Start MM-120 Phase III in 2023 and Obtain FDA Approval In 2026 Dr. Freeman and Other FCM Directors Pledge to Extend Lockup Period For Selling Shares Until June 15, 2026 Time is Running Out to Save MindMed Vote on FCM’s BLUE Proxy to Restore Shareholder Value at MindMed SHERIDAN, Wyo., June 07, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), representing approximately 3.5% of the outstanding common shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed”
